All Articles by Author:

Justin.choi

Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase I Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

[Adverum Biotechnologies, Inc.] Adverum Biotechnologies, Inc. announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase I clinical trial for ADVM-022 for the treatment of wet age-related macular degeneration (AMD).

Open Science Takes On the Coronavirus Pandemic

[Nature Technology Feature] When reports emerged in late 2019 of an outbreak of a new coronavirus centred in Wuhan, China, researchers at the virological-analysis website Nextstrain were ready. The open-source project tracks the spread of viruses through genetic variations in the sequences that scientists find.

Director of US Agency Key to Vaccine Development Leaves Role Suddenly Amid Coronavirus Pandemic

[STAT News] Rick Bright, one of the nation’s leading vaccine development experts and the director of the Biomedical Advanced Research and Development Authority, is no longer leading the organization.

Popular

Unmasking Cancer’s Silent Saboteurs: T Regulatory Cells As Therapeutic Targets in Immunotherapy

[Expert Review of Clinical Immunology] Scientists explore the role of Tregs in the immune system, delve into their contribution to cancer and tumor progression, and highlight therapeutic strategies targeting Tregs, along with innovative delivery systems.

Destruction of VISTA by TRIM25 Ablation in T Cells Potentiates Cancer Immunotherapy

[Cell Research] Researchers unveiled a mechanism for V-domain Ig suppressor of T cell activation (VISTA) regulation in T cells and highlights targeting tripartite motif containing 25 (TRIM25)–VISTA as a potential strategy to enhance tumor immunotherapy.

The IL-1R and NFKBIZ Pathway Mediates Immunoregulatory Responses and Immunotherapy Efficacy in Anaplastic Large Cell Lymphoma

[Leukemia] The authors conducted integrated genome-wide CRISPR-Cas9 loss-of-function screens using CD30-specific CAR-engineered NK cells, alongside a complementary PD-L1 regulator screen, and uncovered a critical role for interleukin-1 receptor signaling in modulating CAR therapy efficacy in both ALK and ALK anaplastic large cell lymphoma.